Decreased response to the mRNA anti-SARS-CoV-2 vaccine in hepatitis B vaccine non-responders and frail patients treated with peritoneal dialysis복막투석을 받은 B형 간염 백신 무반응자 및 허약한 환자에서 mRNA anti-SARS-CoV-2 백신에 대한 반응 감소Article Published on 2022-05-252022-09-12 Journal: Nephrology, dialysis, transplantation : official p [Category] MERS, 진단, [키워드] anti-SARS-CoV-2 Decreased hepatitis B mRNA non-responder patients treated Peritoneal dialysis Vaccine [DOI] 10.1093/ndt/gfac031 PMC 바로가기 [Article Type] Article
Response to three doses of the Pfizer/BioNTech BNT162b2 COVID-19 vaccine: a retrospective study of a cohort of haemodialysis patients in France화이자/바이오엔텍 BNT162b2 코로나19 백신 3회 투여에 대한 반응: 프랑스 혈액투석 환자 집단에 대한 후향적 연구Observational Study Published on 2022-05-182022-09-12 Journal: BMC Nephrology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] Anti-spike blood sample BNT162b2 body mass index booster Clinical practice Cohort Comirnaty coronavirus disease COVID-19 defined dialysis dose Factor France French Haemodialysis humoral humoral immune response identify IgG Immunoglobulin injection Injections kidney mortality rate mRNA vaccine National non-responder of BNT162b2 Patient patients performed Pfizer/BioNTech receive Registered remained Responder response retrospective Retrospective study SARS-CoV-2 serological serum albumin significantly significantly higher study population the mean the median titre U/mL Vaccine vaccine doses venous [DOI] 10.1186/s12882-022-02751-5 PMC 바로가기 [Article Type] Observational Study
Association between history of HBV vaccine response and anti-SARS-CoV-2 spike antibody response to the BioNTech/Pfizer’s BNT162b2 mRNA SARS-CoV-2 vaccine among healthcare workers in Japan: A prospective observational study일본 의료 종사자들 사이에서 BioNTech/Pfizer의 BNT162b2 mRNA SARS-CoV-2 백신에 대한 HBV 백신 반응과 항 SARS-CoV-2 스파이크 항체 반응의 연관성: 전향적 관찰 연구Observational Study Published on 2022-05-162022-09-12 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] 95% confidence interval age Analysis anti-SARS-CoV-2 Antibody Response Antibody titer baseline BNT162b2 BNT162b2 mRNA BNT162b2 vaccine booster dose calculated Comorbidity comparable confidence interval COVID-19 pandemic defined dose doses faster follow-up study HBV healthcare healthcare worker immune response Inadequate long term non-responder participant Patient pharmaceutical prospective observational study protective immunity Protein recruited Responder responses against risk Roche S-protein SARS-CoV-2 SARS-CoV-2 vaccine second dose seroconvert seroconverted single dose tested university vaccination Vaccine vaccine response [DOI] 10.1371/journal.pone.0268529 PMC 바로가기 [Article Type] Observational Study
Immune response to the third COVID-19 vaccine dose is related to lymphocyte count in multiple sclerosis patients treated with fingolimod세 번째 COVID-19 백신 접종에 대한 면역 반응은 핀골리모드로 치료받은 다발성 경화증 환자의 림프구 수와 관련이 있습니다Randomized Controlled Trial Published on 2022-05-012022-09-11 Journal: Journal of Neurology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] Absolute lymphocyte count adaptive adaptive cellular immunity BNT162b2 BNT162b2 vaccine both groups Cell Cellular immune response cellular immunity clinical trial correlated COVID-19 COVID-19 vaccination COVID-19 vaccine develop dose Efficacy fingolimod groups humoral Humoral immunity IgG IgG antibody IgG immune response immune response immune responses in both groups lymphocyte Lymphocyte count majority memory memory B memory B cell Multiple multiple sclerosis non-responder Patient patients patients treated Pfizer positive Protective Randomized randomized clinical trial relapsing SARS-CoV-2 vaccination SARS-CoV-2 vaccine single-center Specific T cell therapy Third BNT162b2 SARS-CoV-2 vaccine dose. Treatment two groups Vaccine were assessed [DOI] 10.1007/s00415-022-11030-0 PMC 바로가기 [Article Type] Randomized Controlled Trial
Very low rate of humoral response after a third COVID-19 vaccine dose in patients with autoimmune diseases treated with rituximab and non-responders to two doses리툭시맙으로 치료받은 자가면역 질환 환자와 2회 접종에 무반응자에서 세 번째 COVID-19 백신 접종 후 체액 반응 비율이 매우 낮음Article Published on 2022-05-012022-09-12 Journal: RMD Open [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] Abstract Arthritis, Rheumatoid Autoimmune disease Autoimmune diseases COVID-19 COVID-19 vaccine dose humoral non-responder Patient rituximab treated vaccination [DOI] 10.1136/rmdopen-2022-002308 PMC 바로가기 [Article Type] Article
B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients기준선에서의 B 세포 특성은 RTX 치료 환자의 예방 접종 반응을 예측합니다Article Published on 2022-04-192022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 진단, [키워드] Algorithm Analysis Antigen presentation Autoimmune B cell B cell subset B cells B-cells baseline carried Cell cellular response Characteristics controls correlation CoV CXCR5 distribution double negative evaluated expressing expression group healthy control HLA-DR humoral identify Immunosuppression increased risk Inflammatory inverse correlation kidney transplant recipient majority marker multidimensional naïve neutralizing antibody non-responder Patient patients performed plasmablast positive correlation predict prediction Predictive predictor receiving Responder responders response rheumatic disease rheumatoid arthritis RTX RTX (rituximab) SARS – CoV – 2 SARS-CoV-2 pandemic Significant Spread subset Therapies therapy transitional B cells UMAP vaccination vaccination response vaccination responses vaccine response [DOI] 10.3389/fimmu.2022.822885 PMC 바로가기 [Article Type] Article
Response to and outcomes of the Pfizer BNT162B2 vaccine in hemodialysis patients-A prospective observational studyObservational Study Published on 2022-04-012022-10-05 Journal: Hemodialysis International. International Symposiu [Category] COVID19(2023년), SARS, 임상, [키워드] Antibody Response Antibody titer BNT162b2 vaccine COVID-19 COVID-19 infection COVID-19 vaccine death dialysis DiaSorin dose evaluated FIVE Hemodialysis high mortality Hospitalization Hospitalized IgG IgG test in both group Infection Italy LIAISON non-responder occurred outcome Patient patients Pfizer prospective observational study Protective rate of infection required Research Responder responders response S1/S2 SARS-CoV-2 SARS-CoV2 second dose Standard the vaccine vaccination Vaccine vaccine response was tested was used [DOI] 10.1111/hdi.13005 PMC 바로가기 [Article Type] Observational Study
BNT162b2 Third Booster Dose Significantly Increases the Humoral Response Assessed by Both RBD IgG and Neutralizing Antibodies in Renal Transplant RecipientsBNT162b2 3차 부스터 용량은 신장 이식 수혜자의 RBD IgG 및 중화 항체 모두에 의해 평가된 체액 반응을 상당히 증가시킵니다Article Published on 2022-03-212022-09-11 Journal: Transplant International [Category] MERS, SARS, 진단, 치료기술, [키워드] 95% CI Allograft antibody Antibody Response BNT162b2 BNT162b2 vaccine booster COVID-19 COVID-19 vaccine develop Diabetic diabetic nephropathy Dilution domain dose effective ESRD geometric mean geometric mean titer geometric mean titers GMT GMTs group had no humoral Humoral response IgG Immunosuppression increase independent predictor independent predictors mycophenolic acid negative and positive nephropathy Neutralizing antibodies neutralizing antibody non-responder non-responders of BNT162b2 Patient positive predictor pseudo-virus RBD RBD IgG Receptor-binding domain recipient recipients remained renal Renal transplantation Responder responders response response rate SARS-CoV-2 secondary to seroconverted significant increase stratified systemic systemic AEs the vaccine Transplant Vaccine were recorded [DOI] 10.3389/ti.2022.10239 PMC 바로가기 [Article Type] Article
Evaluating the antibody response to SARS-COV-2 vaccination amongst kidney transplant recipients at a single nephrology centre단일 신장 센터에서 신장 이식 수혜자의 SARS-COV-2 백신 접종에 대한 항체 반응 평가Research Article Published on 2022-03-102022-09-12 Journal: PLoS ONE [Category] MERS, SARS, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Allograft Analysis antibody Antibody Response Antibody testing appear AZD1222 benefit BNT162b2 Cohort coronavirus Corticosteroid death deaths dose Effectiveness EGFR evaluated Evaluating Final final analysis General population glomerular filtration greater identify Immunosuppression increasing age Infection infections kidney transplant recipient kidney transplant recipients maintenance multivariate mycophenolic acid non-responder non-responders occurred Oxford-AstraZeneca participant Participants Patient performed Pfizer Pfizer-BioNTech pre-vaccination predictor Primary outcome randomized trials recipient Responder responders Result SARS-CoV-2 antibody testing SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 vaccine SARS-CoV-2 vaccines serious complication seroconversion rate seroconversion rates seropositive severe acute respiratory syndrome Coronavirus significantly single center the antibody response Treatment United Kingdom vaccination Vaccine vaccine doses vaccine response Vaccines variable were excluded were recorded [DOI] 10.1371/journal.pone.0265130 PMC 바로가기 [Article Type] Research Article
Trajectories of humoral and cellular immunity and responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy항-CD20 치료 이력이 있는 환자에서 체액성 및 세포성 면역의 궤적과 SARS-CoV-2에 대한 3차 mRNA 백신에 대한 반응Article Published on 2022-03-012022-09-11 Journal: RMD Open [Category] MERS, SARS, 임상, 진단, 치료기술, [키워드] Analysis anti-CD20 anti-CD20 therapy anti-CD20 treatment anti-SARS-CoV-2 immune response anti-SARS-CoV-2 immune responses antibody concentration Antibody concentrations cell-mediated immune Cell-mediated immunity cellular immunity CMI comparable Concentration Control covariance COVID-19 decay dose elicited healthy volunteer healthy volunteers humoral humoral and cell-mediated immunity Humoral response humoral responses IgG immune responses Immunity immunogenicity inefficient interferon interferon-γ investigated Linear regression majority mRNA vaccine non-responder non-responders outcome Participants Patient patients registration number Responder responders response reveal rituximab RNA SARS-CoV-2 SARS-CoV-2 vaccine second vaccination systemic vasculitis Therapies therapy Trajectories trajectory Trial Registration Number vaccination Vaccination strategy Vaccine vaccine dose Vasculitis [DOI] 10.1136/rmdopen-2021-002166 PMC 바로가기 [Article Type] Article